

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO. 03528.0064.00US00	APPLICATION NO. 09/643,168
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE August 21, 2000	GROUP




RECEIVED
APR 25 2002
FBI CENTER 1600/2900

U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
AO	1.	5,654,285	08/05/97	Ingall, et al.	514	47	06/06/95	
AO	2.	5,721,219	02/24/98	Ingall, et al.	514	47	08/09/95	
AO	3.	5,747,496	05/05/98	Cox, et al.	514	258	07/04/96	
AO	4.	5,955,447	09/21/99	Ingall, et al.	514	47	08/28/97	
AO	5.	6,166,022	12/26/00	Brown, et al.	514	258	07/15/98	
FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
AO	6.	WO 92/17488	15.10.92	WO			X	
	7.	WO 94/18216	18.08.94	WO			X	
	8.	WO 97/03084	30.01.97	WO			X	
	9.	WO 98/28300	02.07.98	WO			X	
	10.	WO 00/33080	08.06.00	WO			X	
	11.	WO 00/34283	15.06.00	WO			X	
	12.	WO 01/19826	22.03.01	WO			X	
	13.	WO 01/36421	25.05.01	WO			X	
	14.	WO 01/39781	07.06.01	WO			X	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Howard Chen




4/28/03



<p style="text-align: center;">LIST OF REFERENCES CITED BY APPLICANT</p> <p style="text-align: center;">(See Remarks sheets if necessary)</p> <p style="text-align: center;">PTO FORM 1449</p>	<p>ATTY. DOCKET NO. 03678.0064.US00</p>	<p>APPLICATION NO. 09/643,138</p>
<p>APPLICANT Jose L. BOYER, et al.</p>		
<p>FILING DATE August 21, 2000</p>		<p>GROUP 1614</p>





*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
  	1.	5,049,550	09/17/91	Zamecnik	514	47	11/21/88
	2.	5,292,498	03/08/94	Boucher	424	45	06/19/91
	3.	5,596,088	01/21/97	Boucher, <i>et al.</i>	536	23.5	05/16/95
	4.	5,607,836	03/04/97	Boucher, <i>et al.</i>	435	7.2	05/19/95
	5.	5,628,984	05/13/97	Boucher	424	45	07/31/95
	6.	5,635,160	06/03/97	Stutts, <i>et al.</i>	424	45	06/07/95
	7.	5,656,256	08/12/97	Boucher, <i>et al.</i>	424	45	12/14/94
	8.	5,681,823	10/28/97	Kim, <i>et al.</i>	514	47	05/02/96
	9.	5,691,156	11/25/97	Boucher, <i>et al.</i>	435	7.21	05/19/95
	10.	5,763,447	06/09/98	Jacobus, <i>et al.</i>	514	265	07/23/96
	11.	5,789,391	08/04/98	Jacobus, <i>et al.</i>	514	51	07/03/96
	12.	5,837,861	11/17/98	Pendergast, <i>et al.</i>	536	25.6	02/10/97
	13.	5,900,407	05/04/99	Yerxa, <i>et al.</i>	514	47	02/06/97
	14.	5,902,567	05/11/99	Boucher	424	9.1	12/30/96
	15.	5,935,555	08/10/99	Stutts, <i>et al.</i>	424	45	05/08/97
	16.	5,958,897	09/28/99	Jacobus, <i>et al.</i>	514	49	01/09/98
	17.	5,962,432	10/05/99	LaCroix, <i>et al.</i>	514	47	07/03/96
	18.	5,968,913	10/19/99	LaCroix, <i>et al.</i>	514	47	12/23/97
	19.	5,972,904	10/26/99	Jacobus, <i>et al.</i>	514	51	01/09/98
	20.	5,981,506	11/09/99	Jacobus, <i>et al.</i>	514	47	01/09/98
	21.	6,022,527	02/08/00	Boucher, <i>et al.</i>	424	45	07/13/99
	22.	6,037,343	03/14/00	El-Fehail Ali	514	252	12/22/95
	23.	6,040,317	03/21/00	Duggan, <i>et al.</i>	514	317	12/28/98
	24.	6,133,247	10/17/00	Boucher, <i>et al.</i>	514	50	01/22/97
	25.	6,143,279	11/07/00	Boucher, <i>et al.</i>	424	45	08/28/98
	26.	6,159,952	12/12/00	Shaffer, <i>et al.</i>	514	47	11/07/96

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	03678.0064.US00	09/643,138
	APPLICANT	
	Jose L. BOYER, et al.	
	FILING DATE	GROUP
	August 21, 2000	1614

FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>Ho</i>	27.	WO 00/30629	02/06/00	PCT			X	
	28.	WO 00/39145	06/07/00	PCT			X	
	29.	WO 00/50024	31/08/00	PCT			X	
	30.	WO 94/08593	28/04/94	PCT			X	
	31.	WO 95/10538	20/04/95	PCT			X	
	32.	WO 97/29456	21/08/97	PCT			X	
	33.	WO 97/35591	02/10/97	PCT			X	
	34.	WO 98/03177	29/01/98	PCT			X	
	35.	WO 98/03182	29/01/98	PCT			X	
	36.	WO 98/15835	16/04/98	PCT			X	
	37.	WO 98/19685	14/05/98	PCT			X	
	38.	WO 98/34593	13/08/98	PCT			X	
	39.	WO 98/34942	13/08/98	PCT			X	
	40.	WO 99/01138	14/01/99	PCT			X	
	41.	WO 99/05155	04/02/99	PCT			X	
	42.	WO 99/09998	04/03/99	PCT			X	
	43.	WO 99/32085	01/07/99	PCT			X	
<i>Ho</i>	44.	WO 99/61012	02/12/99	PCT			X	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
	45.	Antiplatelet Trialists' Collaboration., "Collaborative overview of randomised trials of antiplatelet therapy-I : Prevention of Death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients," <i>Br. Med. J.</i> <u>308</u> : 81-106 (1994)						
	46.	Antiplatelet Trialists' Collaboration., "Collaborative overview of randomised trials of antiplatelet therapy-II : Maintenance of Vascular graft or arterial patency by antiplatelet therapy," <i>Br. Med. J.</i> <u>308</u> : 159-168 (1994)						
	47.	Antman, E, for The TIMI 9a investigators, "Hirudin in Acute Myocardial Infarction," <i>Circulation</i> , <u>90</u> (4):1624-1630 (1994)						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p align="center">LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)</p> <p align="center">PTO FORM 1449</p> <p align="center">MAIL DATE CANCELLED FEB 12 2001</p>	ATTY. DOCKET NO. 03678.0064.US00	APPLICATION NO. 09/643,138
	APPLICANT Jose L. BOYER, et al.	
	FILING DATE August 21, 2000	GROUP 1614

48.	Bernat, A., et al., "Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat," <i>Thromb. Haemostas.</i> (1993) <u>70</u> (5):812-816
49.	Bush, L., et al., "Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries," <i>Circulation</i> <u>69</u> (6):1161-1170, (1984)
50.	EPIC investigators, "Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty," <i>New Engl. J. Med.</i> (1994) 330:956-961
51.	Folts, J. et al., "Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Asprian," <i>Circulation</i> <u>54</u> (3):365-370 (1976)
52.	Frederick, L.G., et al., "The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A is Reduced When Used in Combination with Asprian and Heparin in a Canine Model of Coronary Artery Thrombosis," <i>Circulation</i> <u>93</u> (1):129-134 (1996)
53.	Geiger, J., et al., "Specific Impairment of Human Platelet P2Y ac ADP Receptor-Mediated Signaling by the Antiplatelet Drug Clopidogrel," <i>Arterioscler. Thromb. Vasc. Biol.</i> <u>19</u> :2007-2011 (1999)
54.	GUSTO Iia Investigators, The Global Use of Strategies to Open Occluded Coronary Arteries., "Randomized Trial of Intravenous Heparin Versus Recombinant Heparin for Acute Coronary Syndromes", <i>Circulation</i> . <u>90</u> (4): 1631-1637 (1994)
55.	Hass, W., et al., "A Randomized Trial Comparing Ticlopidine Hydrochloride with Asprian for the Prevention of Stroke for High-Risk Patients," <i>N. Engl. J. Med.</i> , <u>321</u> (8):501-507 (1989)
56.	Herbert, J.M. et al., Inhibitory Effect of Clopidogrel on Platelet Adhesion and Intimal Proliferation After Arterial Injury in Rabbits," <i>Arterioscl. Thromb.</i> (1993) <u>13</u> (8):1171-1179
57.	Hourani, et al., The Platelet ADP Receptors Meeting, La Thuile, Italy, March 29-31, 2000
58.	Humphries, R.G., et al., "Pharmacological profile of the novel P2T-Purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vitro," <i>Br. J. Pharmacol.</i> <u>115</u> :1110-1116 (1995)
59.	Ingall, A., et al., "Antagonists of the Platelet P2t Receptor: A Novel Approach to Antithrombotic Therapy," <i>J. Med. Chem.</i> <u>42</u> : 213-220 (1999)
60.	Lazarowski, E., et al., "Pharmacological selectivity of the cloned human P2u-purinoceptor: potent activation by diadenosine tetraphosphate," <i>Brit. J. Pharm.</i> <u>116</u> :1619-1627 (1995)
61.	Lekstrom, J and William R. Bell, "Asprian in the Prevention of Thrombosis," <i>Medicine</i> <u>70</u> (3):161-178 (1991)
62.	Maffrand, J.P., et al., "ADP Plays a Key Role in Thrombogenesis in Rats," <i>Thromb. Haemostas.</i> (1988) <u>59</u> (2):225-230
63.	Mickelson, J.K., et al., "Antiplatelet Antibody [7E3 F(ab') ₂] Prevents Rethrombosis After Recombinant Tissue-Type Plasminogen Activator-Induced Coronary Artery Thrombolysis in a Canine Model," <i>Circulation</i> <u>81</u> (2):617-627 (1990)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p align="center">LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small> PTO FORM 1449</p>	<p>ATTY. DOCKET NO. 03678.0394.US00</p>	<p>APPLICATION NO. 09/643,138</p>
	<p>APPLICANT Jose L. BOYER, et al.</p>	
	<p>FILING DATE August 21, 2000</p>	<p>GROUP 1614</p>

64.	Neuhaus., K. L. et al., "Safety Observations from the Piolet Phase of the Randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study," <i>Circulation</i> , <u>90</u> (4): 1638-1642 (1994)
65.	Olivier, K., et al., "Acute Safety and Effects on Mucociliary Clearance of Aerosolized Uridine 5' - Triphosphate + Amiloride in Normal Human Adults," - <i>Am. J. Respir. Crit. Care Med.</i> <u>154</u> :217-223 (1996)
66.	Quinn, M and Desmond J. Fitzgerald, "Ticlopidine and Clopidogrel," <i>Circulation</i> <u>100</u> (15):1667-1672 (1999)
67.	Romson, J., et al., "Electrical Induction of Coronary Artery Thrombosis in the Ambulatory Canine: A model for IN VIVO Evaluation of Anti-Thrombotic Agents," <i>Thromb. Res.</i> 17:841-853 (1980)
68.	Shebuski, R., et al., "Acceleration of Recombinant Tissue-Type Plasminogen Activator-Induced Thrombolysis and Prevention of Reocclusion by the Combination of Heparin and the Arg-Gly-Asp-Containing Peptide Bitistatin in a Canine Model of Coronary Thrombosis," <i>Circulation</i> <u>82</u> (1):169-177 (1990)
69.	Tschopp, J.F., et al., "Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time," <i>Coron. Artery Dis.</i> <u>4</u> :809-817(1993)
70.	Weber, M., et al., "Low-Dose Aspirin Verses Anticoagulants for Prevention of Coronary Graft Occlusion," <i>Am. J. Cardiol.</i> <u>66</u> :1461-1468 (1990)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.